Overview Request Sample Pages Request Customization Download PDF
You are viewing: Latin America Preimplantation Genetic Testing Market analysis

The Latin America Preimplantation Genetic Testing Market was valued at $18.9 Million in 2025 and projected to reach to $29.5 Million by 2030, representing a compound annual growth rate of 9.4%. Latin America's preimplantation genetic testing market is positioned for sustained growth through 2030, driven by increasing healthcare investments and expanding fertility clinic networks across the region.

Latin America Preimplantation Genetic Testing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Latin America Preimplantation Genetic Testing Market Trends and Insights

  • Latin America's PGT adoption is driven by increasing awareness of genetic screening benefits, rising fertility treatment demand, and improving healthcare infrastructure across the region.
  • In Latin America, the 9.4% compound annual growth rate reflects growing investment in assisted reproductive technologies and expanding access to advanced diagnostic capabilities in key markets including Brazil, Mexico, and Colombia. Latin America's PGT market growth is supported by favorable demographic trends, including delayed childbearing and higher prevalence of genetic disorders requiring screening.
  • Latin America continues to strengthen regulatory frameworks governing genetic testing, which enhances market credibility and patient confidence.
  • The forecast period through 2030 indicates Latin America will see accelerated adoption as fertility clinics expand PGT service offerings and costs become more accessible to middle-income populations across the region..

Key Market Statistics

  • CAGR (2025-2030) 9.4% CAGR
  • Market Size, 2025 ~USD 18.9 Million
  • Forecast, 2030 ~USD 29.5 Million
  • Geography Latin America

Latin America Preimplantation Genetic Testing Market Overview

Strong Regional Growth Trajectory :

Latin America's PGT market is expanding at a 9.4% CAGR, growing from USD 18.9 million in 2025 to USD 29.5 million by 2030, demonstrating robust demand for genetic screening technologies across the region.

Rising Fertility Treatment Demand :

Increasing prevalence of infertility and growing acceptance of assisted reproductive technologies are driving PGT adoption among Latin American couples seeking advanced genetic screening solutions.

Improving Healthcare Infrastructure :

Enhanced medical facilities and expanding access to fertility clinics across Latin America are enabling wider adoption of preimplantation genetic testing services in both urban and emerging markets.

Growing Genetic Awareness :

Rising patient education and healthcare provider knowledge about genetic screening benefits are accelerating PGT market penetration throughout Latin America's fertility treatment landscape.

Latin America Preimplantation Genetic Testing Market Dynamics

  • The market's 9.4% CAGR reflects growing consumer awareness of genetic screening benefits and improving access to advanced reproductive technologies.
  • Brazil and Mexico are emerging as key growth drivers, supported by rising disposable incomes and enhanced healthcare infrastructure.
  • Regulatory improvements and greater insurance coverage for fertility treatments are expected to further accelerate market expansion.
  • The region's younger demographic profile and increasing prevalence of genetic disorders create significant opportunities for PGT service providers and diagnostic companies..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • Latin America's PGT market is valued at USD 18.9 million in 2025 and expected to grow to USD 29.5 million by 2030, representing a 9.4% CAGR.
      • Latin America's market growth is driven by increased fertility treatment demand, improved healthcare infrastructure, and rising genetic screening awareness.
      • Latin America's regulatory environment is strengthening, enhancing market credibility and supporting wider adoption of PGT services.
      • Latin America's middle-income population expansion and declining PGT costs are expected to accelerate market penetration through 2030.

      Preimplantation Genetic Testing Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment SINGLE GENE DISORDERS (Application)
      Forecast Period 2025–2030
      Growth Rate CAGR of 10.5% from 2025 to 2030
      Largest Segment PREIMPLANTATION GENETIC SCREENING (Procedure Type)
      Market Size Base Year (Billions) ~USD 0.69 (2025)
      Revenue Forecast (Billions) ~USD 1.14 (2030)
      Segments Covered Product & Service, Procedure Type, Technology, Application, Type, Type Of Cycle, End User

      Latin America Preimplantation Genetic Testing Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Product & Service

      • Instruments
      • Reagents & Consumables
      • Software & Services

      By Procedure Type

      • Preimplantation Genetic Diagnosis
      • Preimplantation Genetic Screening

      By Technology

      • Comparative Genomic Hybridization
      • Fluorescence In Situ Hybridization
      • Next-Generation Sequencing
      • Polymerase Chain Reaction
      • Single-Nucleotide Polymorphism

      By Application

      • Aneuploidy
      • Gender Identification
      • Hla Typing
      • Single Gene Disorders
      • Structural Chromosomal Abnormalities
      • X-Linked Disorders

      By Type

      • Deletions
      • Duplications
      • Inversions
      • Translocations

      By Type Of Cycle

      • Fresh Donor
      • Fresh Non-Donor
      • Frozen Donor
      • Frozen Non-Donor

      By End User

      • Diagnostic Laboratories
      • Fertility Clinics
      • Hospitals
      • Other End Users

      Target Audience

      • Fertility Clinic Operators : Need market data to assess PGT service demand, plan clinic expansions, and evaluate investment opportunities in genetic testing capabilities across Latin America.
      • Diagnostic & Testing Companies : Require regional market insights to identify growth opportunities, develop localized offerings, and establish distribution partnerships in Latin American fertility markets.
      • Healthcare Investors & PE Firms : Seek comprehensive market analysis to evaluate investment potential in Latin American reproductive health companies and genetic testing service providers.
      • Medical Device & Biotech Manufacturers : Need market sizing and growth forecasts to guide product development, regulatory strategy, and commercial expansion planning in Latin American markets.
      • Healthcare Policy & Regulatory Bodies : Require market intelligence to inform healthcare policy decisions, reimbursement frameworks, and regulatory guidelines for genetic testing services in Latin America.

      Key Companies in the Latin America Preimplantation Genetic Testing Market

      CompanyHQOwnershipStrongest segments
      CIMARON LABELPressure-sensitive paper labels,Film and durable labels,Specialty/custom applications,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLaboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      REVVITYUnited StatesPublic CompanyReagents, Assays, and Consumables,Instruments and Detection/Imaging Platforms,Software, Subscriptions, and Informatics,
      COOPERCOMPANIESUnited StatesPublic CompanySpherical contact lenses,Toric and multifocal contact lenses,Fertility consumables, equipment, and services,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      TAKARA BIO INC.JapanPrivate CompanyResearch reagents for genetic and cellular research,Instruments (PCR instruments and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
      VITROLIFESwedenPublic CompanyIVF media and oil,Labware (dishes, pipettes, tubes, VitroTemp, eWitness-related consumables),Cryopreservation solutions,

      CIMARON LABEL

      Insufficient information provided to generate description.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science, providing laboratory equipment, reagents, and analytical instruments.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company provides life sciences, diagnostics, and applied chemical markets with instruments and software.

      REVVITY

      Revvity is a United States-based public company founded in 1937 with 11,000 employees. The company provides analytical technologies and solutions for research, diagnostics, and applied markets.

      COOPERCOMPANIES

      CooperCompanies is a United States-based public company founded in 1958 with 15,000 employees. The company operates in the medical device sector, primarily focused on contact lenses and eye care products.

      ABBOTT

      Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company is a diversified healthcare manufacturer producing pharmaceuticals, diagnostics, nutritional products, and medical devices.

      TAKARA BIO INC.

      Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company specializes in biotechnology research and development.

      VITROLIFE

      Vitrolife is a Sweden-based public company founded in 1989 with 1,103 employees. The company develops and manufactures products for assisted reproduction and embryo culture.

      Latin America vs. other regions

      HowLatin America compares to the other 3 regional blocs covered in this market.

      North America
      ~USD 350 Million · 10.1% wtd CAGR ·
      Europe
      ~USD 211.4 Million · 11.2% wtd CAGR ·
      Asia Pacific
      ~USD 170.3 Million · 12.4% wtd CAGR ·
      Middle East
      ~USD 14.8 Million · 8.8% wtd CAGR ·

      Countries within Latin America - compare and drill down

      Country2025 size (native)
      BrazilUSD 12.6 Million
      MexicoUSD 6.3 Million
      Rest Of Latin AmericaUSD 10.6 Million

      Country market size visualization

      Brazil
      USD 12.6 Million
      Mexico
      USD 6.3 Million
      Rest Of Latin America
      USD 10.6 Million

      Reasons to Buy this Report

      • Market Size & Growth Data : Access precise market valuations for Latin America's PGT sector with detailed 2025-2030 forecasts, enabling accurate investment planning and competitive positioning strategies.
      • Country-Level Insights : Obtain granular market data for Brazil, Mexico, and Rest of Latin America to identify high-potential markets and tailor market entry strategies by geography.
      • Growth Driver Analysis : Understand key factors fueling Latin America's 9.4% CAGR including healthcare infrastructure improvements, rising fertility awareness, and regulatory developments.
      • Competitive Landscape Intelligence : Benchmark your organization against regional market trends and identify emerging opportunities in Latin America's rapidly expanding genetic testing sector.
      • Strategic Decision Support : Leverage comprehensive market intelligence to support product launches, partnership development, and resource allocation decisions across Latin American markets.

      Frequently asked questions

      What is the current market size of Preimplantation Genetic Testing in Latin America?

      In Latin America, the PGT market was valued at USD 18.9 million in 2025 and is projected to reach USD 29.5 million by 2030.

      What is the growth rate of the PGT market in Latin America?

      Latin America's PGT market is growing at a compound annual growth rate (CAGR) of 9.4% from 2025 to 2030.

      Which countries in Latin America are driving PGT market growth?

      Latin America's largest PGT markets include Brazil, Mexico, and Colombia, where fertility clinics and healthcare infrastructure are most developed.

      What factors are accelerating PGT adoption in Latin America?

      Latin America's PGT adoption is accelerated by rising fertility treatment demand, improved healthcare access, strengthened regulatory frameworks, and declining diagnostic costs.

      How does Latin America's PGT market compare to global growth?

      Latin America's PGT market is growing at 9.4% CAGR, slightly below the global average of 10.5%, reflecting regional market maturity and infrastructure development differences.

      RESEARCH METHODOLOGY

      This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global preimplantation genetic testing market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives, and industry consultants, to obtain and verify important qualitative and quantitative data and evaluate the market’s growth prospects. The global market size estimated through secondary research was cross-checked with inputs from primary research to determine the final market size.

      Secondary Research

      Secondary research was mainly used to gather information for the detailed technical, market, and commercial analysis of the preimplantation genetic testing market. The secondary sources for this study include the World Health Organization (WHO), World Bank, Human Fertilization and Embryology Authority (HFEA), International Federation of Fertility Societies (IFFS), American Society for Reproductive Medicine (ASRM), Australia and New Zealand Assisted Reproduction Database (ANZARD), Centers for Disease Control and Prevention (CDC), Society for Assisted Reproductive Technology (SART), National Health Service (NHS), Indian Fertility Society (IFS), British Fertility Society (BFS), European Society of Human Reproduction and Embryology (ESHRE), Association for Fertility and Reproductive Health (AFRH), German Society of Reproductive Medicine (DGRM), Canadian Fertility & Andrology Society (CFAS), Indian Society for the Study of Reproduction and Fertility (ISSRF), Spanish Fertility Society (Sociedad Española de Fertilidad-SEF), Japan Society for Reproductive Medicine, National Registry of Assisted Reproductive Technology and Surrogacy Registry, Journal of Human Reproductive Sciences, American Congress of Obstetricians and Gynecologists (ACOG), European Society of Human Genetics (ESHG); ACS Journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.

      Secondary data was collected and analyzed to determine the overall size of the global preimplantation genetic testing market, which was then validated through primary research. These sources also provided key information about major players, market classification, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

      Preimplantation Genetic Testing Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the preimplantation genetic testing market. These methods were also used extensively to estimate the size of various market segments.

      Preimplantation Genetic Testing Market

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.

      Market Definition

      Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman's uterus. This is done to test a range of genetic problems that can cause implantation failure, miscarriage, and birth defects in a resulting child.

      Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:

      • Preimplantation genetic screening for abnormal chromosome number (PGT-A)
      • Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
      • Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.

      The study offers an in-depth analysis of the preimplantation genetic testing market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key preimplantation genetic testing product and service providers.

      Stakeholders

      • Contract research organizations (CROs)
      • Contract development and manufacturing organizations (CDMOs)
      • In vitro fertilization (IVF) centers and fertility clinics
      • Life science companies
      • Fertility clinics
      • Academic & research institutes
      • Private research institutes
      • Venture capitalists & investors
      • Market research & consulting firms
      • Government associations
      • Medical institutions & universities
      • Hospitals & clinics

      Report Objectives

      • To define, describe, and forecast the preimplantation genetic testing market based on procedure type, technology, product & service, application, type of cycle, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the preimplantation genetic testing market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the preimplantation genetic testing market
      • To benchmark players within the preimplantation genetic testing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

      Get the Full Preimplantation Genetic Testing Market Report

      Full forecast, segment splits, and company analysis for all Preimplantation Genetic Testing Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status